Log in

Dr.Reddy's Laboratories Stock Price, Forecast & Analysis (NYSE:RDY)

$38.32
-0.18 (-0.47 %)
(As of 11/19/2019 07:43 AM ET)
Today's Range
$38.22
Now: $38.32
$38.57
50-Day Range
$36.96
MA: $38.65
$40.56
52-Week Range
$34.25
Now: $38.32
$42.82
Volume103,666 shs
Average Volume183,962 shs
Market Capitalization$6.35 billion
P/E Ratio23.37
Dividend Yield0.68%
Beta0.22
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone91-40-4900-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.23 billion
Cash Flow$2.69 per share
Book Value$12.21 per share

Profitability

Net Income$272 million

Miscellaneous

Employees21,966
Market Cap$6.35 billion
Next Earnings Date2/7/2020 (Estimated)
OptionableOptionable

Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.


Dr.Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

What is Dr.Reddy's Laboratories' stock symbol?

Dr.Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How were Dr.Reddy's Laboratories' earnings last quarter?

Dr.Reddy's Laboratories Ltd (NYSE:RDY) announced its earnings results on Monday, July, 29th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.40 by $0.18. The company had revenue of $558 million for the quarter. Dr.Reddy's Laboratories had a return on equity of 18.44% and a net margin of 16.20%. View Dr.Reddy's Laboratories' Earnings History.

When is Dr.Reddy's Laboratories' next earnings date?

Dr.Reddy's Laboratories is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Dr.Reddy's Laboratories.

What price target have analysts set for RDY?

8 brokers have issued 1-year target prices for Dr.Reddy's Laboratories' shares. Their forecasts range from $39.00 to $39.00. On average, they expect Dr.Reddy's Laboratories' share price to reach $39.00 in the next year. This suggests a possible upside of 1.8% from the stock's current price. View Analyst Price Targets for Dr.Reddy's Laboratories.

What is the consensus analysts' recommendation for Dr.Reddy's Laboratories?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr.Reddy's Laboratories in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dr.Reddy's Laboratories.

Has Dr.Reddy's Laboratories been receiving favorable news coverage?

Headlines about RDY stock have been trending very negative on Tuesday, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dr.Reddy's Laboratories earned a news impact score of -3.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Dr.Reddy's Laboratories.

Are investors shorting Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,600,000 shares, an increase of 6.7% from the September 30th total of 1,500,000 shares. Based on an average daily trading volume, of 170,300 shares, the short-interest ratio is currently 9.4 days. Approximately 1.0% of the shares of the company are short sold. View Dr.Reddy's Laboratories' Current Options Chain.

Who are some of Dr.Reddy's Laboratories' key competitors?

What other stocks do shareholders of Dr.Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr.Reddy's Laboratories investors own include Siemens (SIEGY), Tata Motors (TTM), Infosys (INFY), Vedanta (VEDL), HDFC Bank (HDB), Merck & Co., Inc. (MRK), Cummins (CMI), GlaxoSmithKline (GSK), ICICI Bank (IBN) and Wipro (WIT).

Who are Dr.Reddy's Laboratories' key executives?

Dr.Reddy's Laboratories' management team includes the folowing people:
  • Mr. Gunupati Venkateswara Prasad, Co-Chairman, MD, CEO & Member of Management Council (Age 59)
  • Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 52)
  • Mr. Saumen Chakraborty, Pres, CFO, Global Head of IT & Bus. Process Excellence and Member of the Mgmt Council (Age 58)
  • Mr. M. V. Ramana, CEO & Head of Branded Markets - India & Emerging Countries and Member of Management Council (Age 50)
  • Mr. Ganadhish Kamat, Exec. VP, Global Head of Quality & Member of Management Council (Age 56)

Who are Dr.Reddy's Laboratories' major shareholders?

Dr.Reddy's Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include Mondrian Investment Partners LTD (0.33%), First Trust Advisors LP (0.09%), Sumitomo Mitsui Trust Holdings Inc. (0.07%), Dorsey Wright & Associates (0.05%), Portland Hill Asset Management Ltd (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.02%).

Which institutional investors are selling Dr.Reddy's Laboratories stock?

RDY stock was sold by a variety of institutional investors in the last quarter, including Mondrian Investment Partners LTD, Zurcher Kantonalbank Zurich Cantonalbank, First Trust Advisors LP, Hexavest Inc., Russell Investments Group Ltd., Envestnet Asset Management Inc., Comerica Bank and Dorsey Wright & Associates.

Which institutional investors are buying Dr.Reddy's Laboratories stock?

RDY stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Quadrant Capital Group LLC, Signaturefd LLC, Wetherby Asset Management Inc., GW&K Investment Management LLC and Parallel Advisors LLC.

How do I buy shares of Dr.Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dr.Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $38.32.

How big of a company is Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories has a market capitalization of $6.35 billion and generates $2.23 billion in revenue each year. The company earns $272 million in net income (profit) each year or $1.64 on an earnings per share basis. Dr.Reddy's Laboratories employs 21,966 workers across the globe.View Additional Information About Dr.Reddy's Laboratories.

What is Dr.Reddy's Laboratories' official website?

The official website for Dr.Reddy's Laboratories is http://www.drreddys.com/.

How can I contact Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]


MarketBeat Community Rating for Dr.Reddy's Laboratories (NYSE RDY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  358 (Vote Underperform)
Total Votes:  622
MarketBeat's community ratings are surveys of what our community members think about Dr.Reddy's Laboratories and other stocks. Vote "Outperform" if you believe RDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Featured Article: Trading Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel